| Hazard Information | Back Directory | [Uses]
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections[1][2]. | [in vivo]
Nirsevimab (10-10000 μg/kg; i.m.) inhibits the antibody response in the respiratory mucosa of mice when pre-administered prior to RSV virus infection[2]. | Animal Model: | 3-week-old female BALB/c mice[2]. | | Dosage: | 10 μg/kg, 100 μg/kg, 1 mg/kg, 10 mg/kg | | Administration: | Intramuscular injection (i.m.); administer medication 24 hours prior to RSV virus exposure | | Result: | Inhibited the secretion of sIgA, mucosal IgA, and mucosal IgG in the offspring subsequent to the initial RSV infection. |
| [References]
[1] Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120. DOI:10.3389/fimmu.2023.1283120
[2] Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374. DOI:10.3389/fimmu.2024.1377374 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
www.biorbyt.com |
|